argenx SE (ARGX) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Argenx Se.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.715 Good morning. My name is Rob and I will be your conference operator today. 00:00:03.715 -- 00:00:06.038 I would like to welcome everyone to the call. 00:00:06.038 -- 00:00:09.823 At this time, all lines have been placed on mute to prevent any background noise. 00:00:09.823 -- 00:00:13.187 After the speaker's remarks, there will be a question and answer session. 00:00:13.187 -- 00:00:18.593 Thank you. I'd now like to introduce Beth DelGiaco, Vice President of Corporate Affairs. 00:00:18.593 -- 00:00:21.554 You may now begin your conference. 00:00:23.038 -- 00:00:28.049 Thank you. Two press releases were issued earlier today, one sharing the positive 00:00:28.049 -- 00:00:33.095 results from our phase three ADAPT Oculus study, and the other which outlines our fourth 00:00:33.095 -- 00:00:37.840 quarter and full year 2025 financial results and business update. 00:00:37.840 -- 00:00:42.886 These can be found on our website along with the presentation for today's webcast. 00:00:42.886 -- 00:00:47.151 Before we begin on slide two, I'd like to remind you that forward-looking statements 00:00:47.151 -- 00:00:52.093 may be presented during this call. These may include statements about our future expectations, 00:00:52.093 -- 00:00:57.121 clinical developments, regulatory timelines, the potential success of our product candidates, 00:00:57.121 -- 00:01:00.546 financial projections, and upcoming milestones. 00:01:00.546 -- 00:01:05.214 Actual results may differ materially from those indicated by these statements. 00:01:05.214 -- 00:01:09.701 Argenix is not under any obligation to update statements regarding the future or to conform 00:01:09.701 -- 00:01:14.213 those statements in relation to actual results unless required by law. 00:01:14.213...